23 articles - From Friday Jun 03 2022 to Friday Jun 10 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Rheumatology (Oxford) |
Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. The frequency of AA amyloidosis has decreased in patients with BS, which is similar to the decrease observed for AA amyloidosis due to other inflammatory and infectious causes. However, AA amyloidosis is a rare, but potentially fatal complication of BS. |
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countries. This project has disseminated the EULAR recommendations for patient education to health professionals across 23 countries. Potential barriers to their application were identified and some are amenable to change, namely training patient education providers and developing evaluation tools. |
Interferon-a-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. Our data suggest that, in eRA, IFN-a can cause a sustained, epigenetically mediated, pathogenic increase in lymphocyte activation and proliferation, and that the IGS is, therefore, a robust prognostic biomarker. Its persistent harmful effects provide a rationale for the initial therapeutic targeting of IFN-a in selected patients with eRA. |
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Multivariable linear regression models were performed to identify variables associated with BMD. Results Data from 1066 patients with iRMD were analysed. GC doses of 7.5 mg/day were negatively associated with BMD, but only in patients with moderate to high disease activity. |
| Arthritis Care Res (Hoboken) |
A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. In patients with SSc, a random forest model can aid in the detection of PH with high sensitivity and specificity, and may allow for better patient selection for RHC, thereby minimizing patient risk. |
Associations between dietary intake of vitamin K and changes in symptomatic and structural changes in patients with knee osteoarthritis. The association of higher vitamin K intake with decreased knee symptoms over 24 months in patients with knee OA suggests that clinical trials examining the effect of vitamin K supplementation for knee OA symptoms are warranted. Whether there is an effect on knee structure is unclear. |
Effectiveness and Safety of Tofacitinib in Canadian Patients with Rheumatoid Arthritis: Primary Results from the Observational CANTORAL Study. Tofacitinib was associated with early and sustained improvement in RA signs and symptoms in real-world patients. Effectiveness and safety were consistent with the established tofacitinib clinical profile. |
Meta-analyses on the effects of Disease Modifying Anti-Rheumatic Drugs on the most relevant Patient-Reported Outcome domains in Rheumatoid Arthritis. DMARDs decrease the burden in al of the domains that are relevant to patients. Effect sizes may be influenced by DMARD type. Therefore, in the decision for rheumatoid arthritis treatment, patient-reported outcomes should be taken into account. |
| Arthritis Res Ther |
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. Methods Patients with GCA who had received = 5 doses of TCZ IV 8 mg/kg Q4W and achieved remission were enrolled. Patients received 5 doses of TCZ IV 7 mg/kg Q4W in period 1 and, if still in remission, 5 doses of 6 mg/kg Q4W in period 2. Pharmacokinetic endpoints were maximum concentration (C was within the range observed in patients with GCA treated with SC dosing every week or every 2 weeks. |
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. In a cohort of patients with established RA and significant comorbidities who taper rituximab after substantial initial disease activity improvement, a low rate of relapses and lower risk of SAEs compared to SD were recorded. Seropositivity, a lower number of previous bDMARDs use, and lower DAS28 at 6 months predicted the probability of entering the LD regimen. |
Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium. Upregulation of semaphorin 3G in the RA synovium is a novel mechanism that exacerbates joint inflammation, leading to further deterioration, through macrophage accumulation. |
| Arthritis Rheumatol |
'Heavy chain constant region usage in antibodies to peptidylarginine deiminase 4 distinguishes disease subsets in rheumatoid arthritis'. Anti-PAD4 IgG1, IgG3 and IgE antibodies identify discrete disease subsets in RA, suggesting that heavy chain usage drives distinct effector mechanisms of anti-PAD4 antibodies in RA. |
Association Between Walking for Exercise and Symptomatic and Structural Progression in Individuals with Knee Osteoarthritis: Data from the Osteoarthritis Initiative Cohort. In individuals > 50 |
Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the United States. We did not find an increase in presumed flares following RZV vaccination. Among adults aged =50 |
Serological Biomarkers of Progression towards Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel. We have demonstrated that imminent diagnosis of RA could be classified with high specificity for healthy controls and ReA cases based on a panel of cytokines measured in serum samples collected within 6 months before actual diagnosis. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Arthritis Rheumatol |
Intracellular sensing of DNA in autoinflammation and autoimmunity. Experimental evidence from genetically-modified murine models further support the ability of endogenous DNA and DNA sensing to drive disease pathogenesis, prompting the question of whether endogenous DNA can also incite inflammation in human autoimmune diseases. Here we review the current understanding of intracellular DNA sensing and downstream signaling pathways as they pertain to autoinflammatory disease, including the development of monogenic disorders such as STING-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutieres Syndrome (AGS). In addition, we discuss systemic rheumatic diseases, including certain forms of systemic lupus erythematosus, familial chilblain lupus and others with established links to intracellular DNA sensing pathways, and highlight the lessons learned from these examples as they apply to the development of therapies targeting these pathways. |
Letters to the editors and authors’ replies
| Arthritis Rheumatol |
all remaining publications eg case reports, images of the month, etc…
| Ann Rheum Dis |
| Arthritis Rheumatol |
| Rheumatology (Oxford) |